Dr. Ferket received his MD from the University of Amsterdam in the Netherlands and an MSc degree in Clinical Epidemiology from the Netherlands Institute for Health Sciences. He holds a PhD in Clinical Epidemiology and Radiology (with a focus on Medical Decision Making) from the Erasmus University Medical Center in Rotterdam.
Education
MD, Academic Medical Center, University of Amsterdam
MSc, Netherlands Institute for Health Sciences
PhD, Erasmus Medical Center, Erasmus University
-
2016
Mentored Clinical and Population Research Award
Dr. Ferket's research focuses on applying quantitative methods to identify the best medical decisions for patient populations and the individual patient. He employs mathematical modeling and computer simulation techniques to estimate health and economic outcomes following healthcare interventions, which can be expected for individual risk profiles based on data from clinical trials, population cohort studies, electronic health records and administrative claims databases. He has performed various decision and prognostic modeling studies to evaluate health benefits, risks and economic outcomes for different chronic, non-communicable disease types with the purpose of a) guiding policy makers in decision making at the population level and b) guiding the individual and his/her physician in selecting the optimal medical option(s). His research particularly concerns: 1) prevention of cardiovascular disease, 2) value of surgical procedures, and 3) utility of novel biomarkers and imaging tests.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Ferket did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.